Cingulate Therapeutics
6
0
0
5
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Low Risk
Score: 25/100
0.0%
0 terminated/withdrawn out of 6 trials
100.0%
+13.5% vs industry average
50%
3 trials in Phase 3/4
40%
2 of 5 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (6)
Phase 3 Efficacy and Safety Laboratory Classroom Study in Pediatrics (6-12) With ADHD Using CTx-1301
Role: lead
Phase 3 Efficacy and Safety Fixed-Dose Study in Pediatrics (6-17) With ADHD Using CTx-1301
Role: lead
Phase 3 Efficacy and Safety Study in Adults With ADHD Using CTx-1301.
Role: lead
In-clinic Crossover Study in Subjects With Two Treatments (Fed vs Fasted)
Role: lead
Fed-Fast Crossover Study to Assess the Effect of Food With CTx-1301 in Healthy Subjects
Role: lead
CTx-1301 Comparative Bioavailability Study
Role: lead
All 6 trials loaded